Panacea Biotec Ltd - 531349 - Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Vinod GoelDesignation :- Company Secretary and Compliance Officer Panacea Biotec Ltd - 531349 - Shareholding for the Period Ended June 30, 2021
Panacea Biotec Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click here PANACEA BIOTEC LTD. - 531349 - Board Meeting Intimation for Approving The Standalone And Consolidated Unaudited Financial Results (Provisional) For The Quarter Ended June 30, 2021
PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2021 ,inter alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter ended June 30, 2021. Further, pursuant to Regulation 46(2) of the SEBI LODR Regulations, notice of the said meeting is also being uploaded on the website of the Company. Further, with reference to our earlier announcement dated June 30, 2021 intimating the Closure of Trading Window pursuant to the Company''s Code of Conduct for Prevention of Insider Trading framed in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, we would like to inform that the trading window of the Company shall remain closed for all Designated Persons of the Company till July 25, 2021 and the same will re-open from July 26, 2021. PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Demise
Dear Sir / Madam, We are deeply grieved to inform that Mr. Ashwini Luthra, Independent Director of the Company has departed for his heavenly abode today i.e. July 13, 2021. The Company expresses its heartfelt condolences for his untimely death and wishes to put on record its sincere and deep appreciation for his invaluable guidance and contribution during his tenure. Accordingly, Mr. Ashwini Luthra has ceased to be director on the Board of Directors of the Company. Kindly take the above information on your record. Panacea Biotec Ltd - 531349 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
This is with reference to CDSL's Operating Instructions for Issuers/RTAs, which states that the Issuer/RTA shall inform the details of the securities dematerialized to all the Stock Exchanges where the securities are listed. Accordingly, we would like to inform you that no share has been dematerialized during the month of June, 2021. A copy of the certificate obtained from the Company's RTA viz. Skyline Financial Services Pvt. Ltd., regarding shares dematerialized as on June 30, 2021 is also enclosed as Annexure -1. Panacea Biotec Ltd - 531349 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed herewith a certificate dated July 03, 2021, issued by Skyline Financial Services Private Limited, Registrar and Transfer Agent of the Company, confirming compliance under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2021.
Panacea Biotec Rallies On Receiving License To Produce Sputnik V Vaccine
The Sputnik V vaccine will be produced at Panacea Biotec's Baddi manufacturing facility in Himachal Pradesh. PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
The Company is delighted to announce the receipt of manufacturing license from Drug Controller General (India) for Sputnik V vaccine against Covid-19 pursuant to its collaboration with Russian Direct Investment Fund (Russia's sovereign wealth fund). Sputnik V was registered in India under the emergency use authorization procedure on April 12, 2021 and vaccination against Covid-19 with the Russian vaccine started on May 14, 2021. Sputnik V has been registered in 67 countries globally with total population of over 3.5 billion people. A copy of the Press Release titled 'Panacea Biotec announces receipt of manufacturing license to produce Sputnik V vaccine at Baddi, Himachal Pradesh' being issued to the media, etc. in this regard is enclosed for your kind reference and record please. Kindly acknowledge the receipt. Panacea Biotec Ltd - 531349 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
The Company is delighted to announce the receipt of manufacturing license from Drug Controller General (India) for Sputnik V vaccine against Covid-19 pursuant to its collaboration with Russian Direct Investment Fund (Russia's sovereign wealth fund). Sputnik V was registered in India under the emergency use authorization procedure on April 12, 2021 and vaccination against Covid-19 with the Russian vaccine started on May 14, 2021. Sputnik V has been registered in 67 countries globally with total population of over 3.5 billion people. A copy of the Press Release titled 'Panacea Biotec announces receipt of manufacturing license to produce Sputnik V vaccine at Baddi, Himachal Pradesh' being issued to the media, etc. in this regard is enclosed for your kind reference and record please. Kindly acknowledge the receipt. Panacea Biotec Ltd - 531349 - Disclosure Under Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed disclosure of related party transactions in the format specified in the relevant accounting standards for half year ended March 31, 2021 on consolidated basis. This is for your kind information and record please.